glimps iqv expand data tool
june attend ia analyst day nyc reiter prior
guid gave updat medium-term guid see tabl first
read note main focu session compani data analyt
toolkit breadth offer bullish use data advanc
analyt world evid transform drug develop clinic trial
link continu see innov leader field link
tabl iqvia updat medium-term guidanc
capital-expenditure defer softwar
revenu
revenu
previous note think iqv strateg invest next-gener ie
smart data-driven clinic develop offer commerci technolog suit
led higher contract win rate market share gain improv backlog convers
overal higher organ revenu growth iqv analyst day well-tim deep
dive special sauc differenti peer reiter buy rate
bump out-year estim rais po
maintain est make upsid tweak ep vs
see larger increas core growth improv forecast
sales/ebitda/ep cagr
assum higher end guidanc would result ep compound-annual-growth-rate due
higher est po increas still base adj ep estimate
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
ia lead global provid
inform technolog solut contract
research servic compani world
largest cro contract research organ
largest sourc drug util data
focus use data advanc analyt
scienc help healthcar stakehold find better
solut patient compani
employe serv client
posit pharma biotech end
market remain healthi addit also
believ abl grow competit
leverag differenti next-gener
clinic develop offer commerci
technolog solut potenti growth
upsid capit deploy
price object base adj ep estim multipl
line histor averag think warrant posit
current cro industri trend risk price object lower biopharma
commerci spend custom consolid data suppli secur risk competit
technolog risk execut risk regulatori risk
derik de bruin herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
us life scienc diagnost tool anim health coverag cluster
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
